Equities

Novo Integrated Sciences Inc

NVOS:NAQ

Novo Integrated Sciences Inc

Actions
Health CareHealth Care Providers
  • Price (USD)0.309
  • Today's Change-0.019 / -5.79%
  • Shares traded218.84k
  • 1 Year change-88.45%
  • Beta-0.6912
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Novo Integrated Sciences Inc grew revenues 7.11% from 11.74m to 12.57m while net income improved from a loss of 32.85m to a smaller loss of 13.21m.
Gross margin37.68%
Net profit margin-180.11%
Operating margin-77.47%
Return on assets-68.51%
Return on equity-133.23%
Return on investment-113.88%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Novo Integrated Sciences Inc fell by 1.76m. Cash Flow from Financing totalled 763.86k or 6.08% of revenues. In addition the company used 2.24m for operations while cash used for investing totalled 49.22k.
Cash flow per share-1.30
Price/Cash flow per share--
Book value per share0.5225
Tangible book value per share-0.6433
More ▼

Balance sheet in USDView more

Novo Integrated Sciences Inc has a Debt to Total Capital ratio of 20.93%, a higher figure than the previous year's 0.24%.
Current ratio0.2717
Quick ratio0.2227
Total debt/total equity0.2569
Total debt/total capital0.2093
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.